32.99

0.24% -0.08

Pharvaris Nv (PHVS)

Overview News Price History Discussions Forecast

Pharvaris Nv stock is traded at $32.99, with a volume of 948.94K. It is down -0.24% in the last 24 hours and down -11.58% over the past month. Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Previous Close:

$33.07

Open:

$32.88

24h Volume:

948.94K

Relative Volume:

1.31

Market Cap:

$2.32B

Revenue:

Net Income/Loss:

$-195.21M

P/E Ratio:

-10.39

EPS:

-3.1763

Net Cash Flow:

$-176.19M

1W Performance:

-13.18%

1M Performance:

-11.58%

6M Performance:

+30.19%

1Y Performance:

+35.09%

1-Day Range:

$31.91

$33.84

1-Week Range:

$31.91

$38.20

52-Week Range:

$20.65

$43.25

Pharvaris Nv Stock (PHVS) Company Profile

Name

Pharvaris Nv

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

Address

Employee

129

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

PHVS's Discussions on Twitter

Compare PHVS vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHVS Pharvaris Nv	32.99	2.32B	0	-195.21M	-176.19M	-3.1763
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Wolfe Research	Outperform
Mar-09-26	Initiated	RBC Capital Mkts	Outperform
Oct-15-25	Initiated	H.C. Wainwright	Buy
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral
Jun-11-25	Initiated	Guggenheim	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Sep-25-23	Initiated	Wedbush	Outperform
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-05-22	Initiated	Bryan Garnier	Buy
Sep-13-22	Resumed	JMP Securities	Mkt Outperform
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform
May-25-22	Initiated	JMP Securities	Mkt Outperform
Mar-02-21	Initiated	BofA Securities	Neutral
Mar-02-21	Initiated	Morgan Stanley	Overweight
Mar-02-21	Initiated	Oppenheimer	Outperform
Mar-02-21	Initiated	SVB Leerink	Outperform

View All

Pharvaris Nv Stock (PHVS) Latest News

Sep 23, 2026

A Pharvaris (PHVS) director proposes selling shares valued at $395,524. - Stock Titan

Sep 23, 2026

Form 4 Pharvaris N.V. For: 23 September - Investing.com India

Sep 23, 2026

Form 4 Pharvaris N.V. For: 23 September By Investing.com - Investing.com Nigeria

Sep 23, 2026

Trade Alert: Independent & Non-Executive Vice Chairman Of Pharvaris Hans J. G. C. Schikan Has Sold Stock - simplywall.st

Sep 23, 2026

Sep 22, 2026

(PHVS) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com

Sep 22, 2026

Planned $7M Pharvaris (NASDAQ: PHVS) stock sale disclosed for founder shares - Stock Titan

Sep 22, 2026

After $7M stock sale, Pharvaris (NASDAQ: PHVS) director plans more - Stock Titan

Sep 22, 2026

Form 4 Pharvaris N.V. For: 22 September By Investing.com - Investing.com India

Sep 22, 2026

Pharvaris (PHVS) Insider Trading Activity 2026 - MarketBeat

Sep 22, 2026

Sep 21, 2026

Pharvaris (NASDAQ: PHVS) officer plans Rule 144 sale of 6,000 shares - Stock Titan

Sep 21, 2026

Pharvaris (PHVS) CEO buys 300,000 shares in rights exercise - Stock Titan

Sep 21, 2026

Pharvaris Chief Early Development Anne Lesage disposes of USD 765,466 in common shares - Bitget

Sep 21, 2026

Sep 20, 2026